Literature DB >> 30011414

Pathogenic Mechanisms and Clinical Correlations in Autoimmune Myasthenic Syndromes.

Hakan Cetin1,2, Angela Vincent1.   

Abstract

Autoimmune myasthenic syndromes are antibody-mediated disorders of the neuromuscular junction. Common antigenic targets are the acetylcholine receptor or muscle specific kinase (MuSK) in myasthenia gravis (MG) and the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. There is evidence that antibodies directed against other antigens such as low-density lipoprotein receptor-related protein 4 (LRP4) are also involved in MG. The mechanisms by which various antibodies exert their pathogenic effect depend on the IgG subclass and also the epitope location on the antigens. These mechanisms are partly heterogeneous and include antigen degradation, complement activation, direct functional blocking, or disruption of protein-protein interactions. The neuromuscular junction is characterized by a structural and functional plasticity that is able to compensate for some of the neuromuscular junction defects. Here, we discuss the underlying pathogenic mechanisms of the different autoantibodies and correlate them with phenotypic features. The understanding of these elements should help guide the clinical management of patients with autoimmune myasthenic syndromes. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30011414     DOI: 10.1055/s-0038-1660500

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  9 in total

Review 1.  Complement Inhibitor Therapy for Myasthenia Gravis.

Authors:  Khaled Albazli; Henry J Kaminski; James F Howard
Journal:  Front Immunol       Date:  2020-06-03       Impact factor: 7.561

Review 2.  Muscle-Specific Kinase Myasthenia Gravis.

Authors:  Lucia S Borges; David P Richman
Journal:  Front Immunol       Date:  2020-05-08       Impact factor: 7.561

3.  Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs.

Authors:  Hakan Cetin; Richard Webster; Wei Wei Liu; Akiko Nagaishi; Inga Koneczny; Fritz Zimprich; Susan Maxwell; Judith Cossins; David Beeson; Angela Vincent
Journal:  J Neurol Neurosurg Psychiatry       Date:  2020-03-12       Impact factor: 10.154

4.  Rapsyn facilitates recovery from desensitization in fetal and adult acetylcholine receptors expressed in a muscle cell line.

Authors:  Hakan Cetin; Wei Liu; Jonathan Cheung; Judith Cossins; An Vanhaesebrouck; Susan Maxwell; Angela Vincent; David Beeson; Richard Webster
Journal:  J Physiol       Date:  2019-06-17       Impact factor: 5.182

5.  Two polymorphic mutations in promoter region of DNA polymerase β in relatively higher percentage of thymic hyperplasia patients.

Authors:  Qingjun Wu; Shan Zhou; Jian Liu; Hongfeng Tong; Yaoguang Sun; Wenxin Tian; Hanbo Yu; Chuan Huang; Donghang Li; Peng Jiao; Chao Ma; Jianping Cai; Dapeng Dai
Journal:  Thorac Cancer       Date:  2020-12-13       Impact factor: 3.500

6.  Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability.

Authors:  Masaharu Takamori
Journal:  Front Mol Neurosci       Date:  2020-05-28       Impact factor: 5.639

Review 7.  The Structure, Function, and Physiology of the Fetal and Adult Acetylcholine Receptor in Muscle.

Authors:  Hakan Cetin; David Beeson; Angela Vincent; Richard Webster
Journal:  Front Mol Neurosci       Date:  2020-09-08       Impact factor: 5.639

Review 8.  Complement in neurological disorders and emerging complement-targeted therapeutics.

Authors:  Marinos C Dalakas; Harry Alexopoulos; Peter J Spaeth
Journal:  Nat Rev Neurol       Date:  2020-10-01       Impact factor: 42.937

9.  Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers.

Authors:  Desmond Y H Yap; Jojo Hai; Paul C H Lee; Xueying Zhou; Michael Lee; Yu Zhang; Meng Wang; Xiaoxiang Chen
Journal:  Clin Transl Sci       Date:  2021-07-16       Impact factor: 4.689

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.